Glaukos

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Earnings data Q1 2023

Earnings data Q2 2023

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose® TR.

Glaukos Submits New Drug Application to U.S. FDA for iDose TR

Glaukos' (GKOS) Q4 revenues beat estimates but fall year over year. Lower revenues, along with higher expenses, hurt margins.

Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y

Glaukos Corporation (NYSE:GKOS ) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns – Chief Executive Officer Alex Thurman – Chief Financial Officer Joe Gilliam – President and Chief Operating Officer Conference Call Participants Ryan Zimmerman – BTIG Tom Stephan – Stifel Larry Biegelsen – Wells Fargo George Sellers – Stephens, Inc. Margaret Kaczor – William Blair Phil Dantoin – Piper Sandler David Saxon – Needham & Company Allen Gong – JPMorgan Anthony Petrone – Mizuho Group Operator Welcome to Glaukos Corporation's Fourth Quarter and Full Year 2022 Financial Results Conference Call. A copy of the company's press release and quarterly summary document both issued after the market close today are available at www.glaukos.com.

Glaukos Corporation (GKOS) Q4 2022 Earnings Call Transcript

Glaukos (GKOS) delivered earnings and revenue surprises of 5.36% and 5.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022. Key highlights include: Net sales of $71.2 million in Q4 2022. Glaucoma net sales of $52.9 million and Corneal Health net sales of $18.3 million in Q4 2022.

Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Citi Healthcare Conference on Wednesday, March 1, 2023, at 1:15 p.m. ET in New York City.

Glaukos Announces Participation in the Citi Healthcare Conference

ALISO VIEJO, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 22, 2023.

Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22

ALISO VIEJO, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive results for a prospective, multi-center clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose® TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the Phase 2b clinical trial (referred to as the “exchange trial”).

Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

ALISO VIEJO, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive clinical updates for several of its Corneal Health pipeline programs, including the commencement of subject enrollment in a second Phase 3 confirmatory trial for Epioxa™ (Epi-on™), and promising initial results from the company's Phase 2a clinical trial for GLK-301 (iLution - Dry Eye Disease).

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

ALISO VIEJO, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 41st Annual J.P Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PT in San Francisco, CA.

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.

3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?

After losing some value lately, a hammer chart pattern has been formed for Glaukos (GKOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Glaukos (GKOS) Could be Great Choice for a Bottom Fisher

Glaukos Announces Participation in the Stephens Annual Investment Conference

Glaukos Corporation (NYSE:GKOS ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Chris Lewis - Vice President-Investor Relations & Corporate Affairs Tom Burns - Chairman & Chief Executive Officer Joe Gilliam - President & Chief Operating Officer Alex Thurman - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Tom Stephan - Stifel George Sellers - Stephens Inc Allen Gong - JPMorgan Operator Welcome to the Glaukos Corporation Third Quarter 2022 Financial Results Conference Call. Copies of today's press release and quarterly summary document, both issued after the market closed today at www.glaukos.com.

Glaukos Corporation (GKOS) Q3 2022 Earnings Call Transcript

Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.

Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View

Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos Corporation Announces Third Quarter 2022 Financial Results

ABIOMED

Masimo

Nevro

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

4 MedTech Stocks Set to Outpace Q3 Earnings Estimates

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30 - October 3, 2022 in Chicago, IL. Key Glaucoma Presentations: Bryan CH Ang, MD Novel Use of t

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Investors were cheered by the latest update from the lab.

News for Glaukos Stock (GKOS)